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Ultraviolet A (320–400 nm) Modulation of Ultraviolet B
(290–320 nm)-Induced Immune Suppression Is Mediated by
Carbon Monoxide
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Accumulating evidence suggests that suberythemogenic ultraviolet A (UVA) (320–400 nm) exposure protects
against the immunosuppressive effect of ultraviolet B (290–320 nm) radiation or its epidermal photoproduct, cis-
urocanic acid (cis-UCA). In skin, UVA photoimmunoprotection is mediated by the inducible antioxidant stress
enzyme, heme oxygenase-1 (HO-1), which degrades heme into carbon monoxide (CO), iron, and biliverdin (reduced
to bilirubin), and is important for cell survival under conditions of oxidative stress. The identity of the HO enzymatic
product(s) that provide the immunoprotection is unknown. Here we examine the potential of CO to fulﬁll this role in
hairless mouse skin, utilizing a novel CO-releasing molecule (CO-RM) to deliver CO to the skin topically. The CO-
RM released CO gradually from the lotion vehicle during 3 h following its preparation, and between 50 and 500 lM,
concentration-dependently protected mice against the suppression of contact hypersensitivity by either solar-
simulated UV radiation (SSUVR) or cis-UCA, whereas aged CO-depleted CO-RM was inactive. Thus, the CO-RM
treatment mimicked UVA-photoimmunoprotection, and identiﬁed HO-released CO as the protective mediator, pro-
viding evidence that the murine cutaneous immune system is modulated by this gaseous messenger. Preliminary
evidence for involvement of guanylyl cyclase was obtained by treatment of the mouse with its specific inhibitor 1H-
(1,2,4)oxadiazolo-(4,3-1)quinoxaline-1-one, which abrogated UVA photoimmunoprotection.
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The immunological outcome of ultraviolet A (UVA) (320–400
nm) exposure of the skin remains controversial. Evidence
exists for its immunosuppressive action in mice (Bestak and
Halliday, 1996; Iwai et al, 1999; Ngheim et al, 2001) and in
humans (Damian et al, 1999; Dumay et al, 2001), but also for
a lack of effect in mice (Aubin et al, 1991; Reeve et al, 1998)
and humans (Skov et al, 1997). In addition to this confusion,
a number of studies in mice indicate that the UVA wave-
band, when administered at environmentally relevant sub-
erythemogenic doses, is itself immunologically inert but can
provide protection against the immunosuppressive effects
of ultraviolet B (UVB) (290–320 nm) irradiation, or of the
epidermal UVB photoproduct, cis-urocanic acid (cis-UCA)
(Reeve et al, 1998; Garssen et al, 2001; Khaskhely et al,
2001). There is now supporting evidence for this phenom-
enon also in humans (Skov et al, 2000).
Subsequently, it has been demonstrated (Reeve and
Tyrrell, 1999) that the UVA photoimmunoprotection in the
mouse is mediated by increased levels of the stress enzyme
heme oxygenase (HO). HO is a redox-regulated enzyme
catalyzing the degradation of heme, releasing biliverdin
(which is rapidly converted to bilirubin by the ubiquitous
biliverdin reductase), free Fe and the gaseous molecule,
carbon monoxide (CO) (Maines, 1997). Two isoforms of HO
have been found in the skin, constitutive HO-2 and induc-
ible HO-1, which responds to a variety of oxidative stress-
ors, including UVA radiation. In mouse skin, HO-1 mRNA
and protein were induced in response to suberythemogenic
UVA exposure, but were otherwise not detectable and did
not respond to UVB irradiation (Allanson and Reeve, 2004).
Both HO isoforms provide the same enzymological activity,
and can be effectively inhibited in the mouse by the injection
of the substrate antagonist Sn protoporphyrin-IX (SnPP),
but the immunological properties of HO appear to be be-
cause of the induced HO-1 only (Reeve and Tyrrell, 1999)
because SnPP did not alter the normal immune response in
non-UV-irradiated mice.
How the products of HO enzyme activity might modulate
immune function has remained unclear. Bilirubin has well-
described antioxidant potential (Stocker et al, 1987) and
might be immunoprotective like other identified antioxidants
such as vitamin C and vitamin E (Gensler and Magdaleno,
1991; Nakamura et al, 1997); free Fe poses an oxidative
hazard, but is rapidly sequestered by ferritin (Vile and Tyrrell,
1993), whereas CO is now recognized as a potent signalling
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molecule that has anti-inflammatory (Otterbein et al, 2000),
anti-apoptotic (Brouard et al, 2000), anti-proliferative (Pey-
ton et al, 2002; Song et al, 2002; Durante, 2003), and im-
mune modulating (Van Uffelen et al, 1996; Di Bello et al,
1998; Ndisang et al, 1999) properties.
In this study, we examine the possible role of CO in me-
diating the UVA protective effect against immunosuppres-
sion caused by solar-simulated UV radiation (SSUVR) or its
cutaneous photoproduct, cis-UCA. Mice were treated top-
ically with a unique CO-releasing molecule (CO-RM), and its
effect on immune function that was compromised by
SSUVR or cis-UCA treatment was measured by the con-
tact hypersensitivity (CHS) reaction. In addition, specific in-
hibitors of the two possible known targets for endogenously
produced CO in other tissue systems, soluble guanylyl
cyclase and the p38 of mitogen-activated protein kinase
(MAPK), were used in the mouse to help characterize the
cutaneous CO-dependent pathway.
Results
Slow degradation of the CO-RM A complete color change
of the CO-RM in dimethyl sulfoxide (DMSO) solution, from
yellow to colorless, occurred gradually within 60 min in open
air at room temperature (Fig 1). We surmised that CO may
therefore be released slowly from the base lotion also, and
be available for a period after topical application for delivery
into the skin layers, perhaps including the dermis, to me-
diate biological effects. In sealed or closed containers, the
color change of the CO-RM/DMSO solution was observed
to take much longer (not shown). The effect of the lotion
emulsion on the release of CO from the CO-RM was not
tested, but the lotion in the applicator syringe barrel, in
which air was excluded, remained yellow during the treat-
ments, and converted to white only when discarded into air
contact after daily use.
Lotions containing increasing concentrations of either
fresh or aged CO-RM were tested for possible immuno-
modulatory effects from topical application (Fig 2). Fresh
CO-RM lotions were not significantly immunosuppressive.
The highest tested concentration of the aged CO-RM lo-
tions, 500 mM, did reveal a slight but significant suppression
of CHS (p¼ 0.017 by ANOVA), but the Tukey test showed no
significant difference; therefore, the biological relevance is
uncertain.
CO-RM protects against SSUVR- or cis-UCA-induced
immunosuppression Irradiation with SSUVR resulted in
32% suppression of CHS (Fig 3). Treatment with 500 mM
CO-RM lotion did not significantly affect CHS, but markedly
reduced the SSUVR-induced immunosuppression to 15%
suppression; p¼0.003. In mice in which HO enzyme activity
Figure 1
Time release of CO from the CO-RM. Slow decrease of absorbance
over time by carbon monoxide-releasing molecule (CO-RM) in dimethyl
sulfoxide, indicative of slow release of CO from the solution.
Figure2
Effect of fresh and aged CO-RM lotions on CHS. Contact hyper-
sensitivity response to oxazolone in groups of five mice treated with
increasing concentrations of fresh carbon monoxide-releasing mole-
cule (CO-RM) (no significant differences) and aged CO-RM lotions,
which became slightly immunosuppressive at 500 mM.
Figure3
Effect of CO-RM lotion on SSUVR-supressed CHS in the presence
of the endogenous HO inhibitor SnPP. Contact hypersensitivity re-
sponse to oxazolone in groups of five mice immunosuppressed by
solar-simulated ultraviolet radiation (SSUVR) exposure, showing the
partial protective effect of 500 mM carbon monoxide-releasing molecule
(CO-RM) lotion, but not of 500 mM aged CO-RM lotion. Inhibition of
endogenous heme oxygenase activity by injection of Sn pro-
toporphyrin-IX (SnPP) slightly exacerbated SSUVR immunosuppres-
sion, but did not alter the CO-RM protection.
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was inhibited by injection with SnPP, the SSUVR was sim-
ilarly immunosuppressive (48% suppression) as without
SnPP treatment (p¼ 0.102). Application of 500 mM CO-RM
again effectively (po0.0001) reduced the SSUVR suppres-
sion to 18%, similar to the protection without SnPP inhibi-
tion, indicating that the protective effect was because of the
exogenous CO-RM and had no significant contribution from
endogenously produced CO. The aged CO-RM lotion ap-
peared to protect slightly from SSUVR suppression of CHS,
but this was not statistically significant.
Consistent with the responses to SSUVR, the topical
application of cis-UCA resulted in 23% suppression of CHS
(Fig 4; p¼0.028), and this was abrogated by 500 mM CO-
RM lotion (p¼ 0.001). In the presence of SnPP the sup-
pression by cis-UCA (31% suppression) was not signifi-
cantly different, and again the suppression was abrogated
by 500 mM CO-RM. The protection by the CO-RM against
cis-UCA was thus more complete than against SSUVR,
suggesting that other contributing mediators of photoim-
munosuppression, such as prostaglandins, may be less
sensitive to the CO-dependent pathways. This is consistent
with the superior protection by UVA radiation against cis-
UCA compared with UVB-induced suppression of CHS that
we have previously observed (Reeve and Tyrrell, 1999).
Thus the results show that the immunosuppressive ef-
fects of SSUVR or its immunosuppressive photoproduct,
cis-UCA, were strongly inhibited by the presence of the
exogenous source of CO, independent of endogenous
HO activity, and that the CO-RM treatment mimicked
the immunoprotective role of UVA-induced HO activity in
the skin.
CO-RM protection against cis-UCA immunosuppression
is concentration dependent The topical application of 50
mM CO-RM contributed no significant protection (42% sup-
pression of CHS) against cis-UCA-induced immuno-
suppression (49% suppression). A clear significant dose
response could be seen, however, with 125, 250, and 500
mM CO-RM (Fig 5), as the degree of immunosuppression
reduced from 49% to 27%, 24% and 14%, respectively
(p¼0.019, 0.021, po0.0001, respectively) and the protec-
tive effect by 500 mM CO-RM restored the CHS reaction to a
level not significantly different from the control level.
Effect of inhibitors of guanylyl cyclase and p38
MAPK Topical application of the selective guanylyl cyclase inhi-
bitor 1H-(1,2,4)oxadiazolo-(4,3-1)quinoxaline-1-one (ODQ)
did not alter the CHS response. The 52% suppression of
CHS induced by SSUVR was reduced to only 20% sup-
pression by UVA radiation (Fig 6). In the presence of ODQ,
Figure 4
Effect of CO-RM lotion on cis-UCA supressed CHS in the presence
of the endogenous HO inhibitor SnPP. Contact hypersensitivity re-
sponse to oxazolone in groups of five mice immunosuppressed by
topical cis-urocanic acid (cis-UCA), showing the complete protective
effect of 500 mM carbon monoxide-releasing molecule (CO-RM) lotion,
but not of 500 mM aged CO-RM lotion. Inhibition of endogenous heme
oxygenase activity by injection of Sn protoporphyrin-IX did not alter
either cis-UCA immunosuppression, or the CO-RM protection.
Figure5
CO-RM concentration dependence for immunoprotection against
cis-UCA. Contact hypersensitivity response to oxazolone in groups of
five mice immunosuppressed by topical cis-urocanic acid, and the
concentration-dependent protective effect of increasing carbon mon-
oxide-releasing molecule lotion concentration.
Figure6
Effect of quanylyl cyclase inhibitor ODQ on UVA photoimmuno-
protection. Contact hypersensitivity response to oxazolone in groups
of five mice immunosuppressed by solar-simulated ultraviolet radiation
exposure, showing the protective effect of ultraviolet A (320–400 nm)
(UVA) irradiation, and the inhibition of the UVA protection by the guanylyl
cyclase inhibitor 1H-(1,2,4)oxadiazolo-(4,3-1)quinoxaline-1-one.
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however, this immune protection was significantly inhibited,
and the CHS response remained suppressed by 44%
(po0.0001). Assay of the cutaneous guanosine 30,50-cyclic
monophosphate (cGMP) levels following daily CO-RM ap-
plication for 3 d showed an ODQ-inhibitable increase of
34% (Table I), providing support for the availability of
CO from topical CO-RM lotion and its action on guanylyl
cyclase. In contrast, topical application of the p38 inhibitor
4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl-5-4-(4-pyridyl)
1H-imidazole (SB203580) was apparently, but not signifi-
cantly immunopotentiating itself (Fig 7; p¼ 0.13). Under
conditions of 54% suppression of CHS by SSUVR, and the
reduction of this to 7% suppression by UVA plus SSUVR,
the SB203580 treatment was not inhibitory and even slightly
(p¼ 0.009) but significantly enhanced the UVA immunopro-
tection against SSUVR. But this response did not differ from
UVA plus SB203580 in the absence of SSUVR (p¼ 0.96);
therefore, the small enhancement of UVA immunoprotection
may not be biologically significant. Thus, these experiments
provide evidence that UVA photoimmunoprotection may act
by the stimulation of the guanylyl cyclase system by CO, but
do not support the involvement of the p38 MAPK pathway.
Discussion
The study of the effects of gaseous CO on tissues has
called for innovative strategies for the presentation of CO
experimentally. For in vitro studies, CO has been bubbled
into culture media, and inhalation of controlled amounts of
CO gas has been used for rodent studies. But inhaled CO
will be delivered to tissues as carboxyhemoglobin, and its
availability to cells will be affected by oxygen tension, and
biological half-life of CO in the blood of 2–5 h (reviewed by
Von Burg, 1999). Recently, Motterlini et al (2002) have
described a novel approach with the use of transition
metal carbonyls as CO-RM, and have demonstrated that
the CO-RM could sustain vasodilatation in precontracted
aortic rings, attenuate coronary vasoconstriction in the
heart ex vivo, and significantly reduce acute hypertension
in vivo (Motterlini et al, 2002). Therefore, we have tested the
CO-RM, choosing topical application for the first time, to
facilitate the direct presentation of the CO to the target tis-
sue, the skin. More recently, a water-soluble CO-RM has
been developed by the Motterlini et al group (Clark et al,
2003) and shown to liberate CO when infused intravenously
in mice, and to have no toxic effect on heart function or
blood pressure, nor to increase carboxyhemoglobin levels
in the blood (Guo et al, 2004).
Our experiments have demonstrated that the topically
applied CO-RM could reproduce the immunoprotective ef-
fect of UVA irradiation against both SSUVR exposure or
cis-UCA in the mouse. Because it is established that UVA
irradiation induces both HO-1 mRNA and HO enzyme ac-
tivity in mouse skin (Allanson and Reeve, 2004) and in cul-
tured human skin fibroblasts (Applegate et al, 1995), and in
the mouse the capacity of UVA radiation to afford such
photoimmunoprotection could be attributed largely to the
induced HO activity, we conclude that the product of HO
activity, the gaseous molecule CO, is the immunoprotective
factor. Inhibition of the endogenous HO enzyme activity by
injecting the mice with its inhibitor SnPP eliminated any
contribution by a possible CO-RM induction of HO-1 via a
hypoxia mechanism, as has been observed by others (Mu-
rphy et al, 1991; Carraway et al, 2000). An immunoregulatory
role for CO has been found by others in studies in which
exogenously applied CO has been shown to prevent pro-
inflammatory cytokine production (Otterbein et al, 2000)
and to suppress allograft rejection in mouse-to-rat cardiac
transplants (Sato et al, 2001). In these studies, the appli-
cation of CO appears to have stimulated immunosuppres-
sive pathways, whereas our model is evidence for CO
protection against immunosuppression. Although this ap-
pears to be incongruous, it is reminiscent of the inducibility
of HO-1 under the opposite conditions of hypoxia and
hyperoxia (Clark et al, 2000; Motterlini et al, 2000), and
might indicate the capacity of HO-1-derived CO to restore
cellular and tissue immunological homeostasis from either
stressor. This response to the CO-RM, [Ru(CO)3Cl2]2 ap-
plied directly to the target organ, the skin, constitutes a new
in vivo model of the biological effector that to date has been
demonstrated mainly in vitro, and in vivo only in the miti-
gation of acute hypertension induced by L-NAME in the rat
(Motterlini et al, 2002). The latter effect was achieved by
the intravenous injection in the rat of 20 mmol per kg of the
Figure 7
Effect of p38 MAPK inhibitor SB 203580 on UVA photo immuno-
protection. Contact hypersensitivity response to oxazolone in groups
of five mice immunosuppressed by solar-simulated ultraviolet radiation
exposure, showing the protective effect of ultraviolet A (320–400 nm)
irradiation, and the failure to alter this protection by the p38 mitogen-
activated protein kinase inhibitor 4-(4-fluorophenyl)-2-(4-methylsulfinyl-
phenyl-5-4-(4-pyridyl) 1H-imidazole.
Table I. CO-RM lotion application daily for 3 d upregulated the
production of cutaneous cGMP (measured by ELISA), which
was prevented by the soluble guanylyl cyclase inhibitor, ODQ
Treatment
cGMP concentration pmol per mL
per g skin (wet weight)
Nil 1.56  0.19
CO-RM 2.09  0.21
CO-RMþODQ 1.03  0.16
CO-RM, carbon monoxide-releasing molecule; ODQ, 1H-(1,2,4)ox-
adiazolo-(4,3-1)quinoxaline-1-one; cGMP, guanosine 30,50-cyclic mono-
phosphate.
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CO-RM. Very recently, a newly synthesized water-soluble
CO-RM, tricarbonylchloro(glycinato)ruthenium administered
intraperitoneally to mice at 40 mg per kg, which we estimate
to be approximately equivalent to 60 mmol per kg of the
non-glycinated [Ru(CO)3Cl2]2 CO-RM, was shown to pro-
vide protection from cardiac allograft rejection in mice, thus
demonstrating that the transition metal tricarbonyl can pro-
vide the CO for an immunoregulatory role (Clark et al, 2003).
These concentrations were somewhat higher than in our
study, where the topical CO-RM was immunologically pro-
tective in the mouse at concentrations of 125–500 mM,
equivalent to 1.0–4.0 mmol per kg. The mechanism of CO
liberation from the CO-RM, however, appears to be deter-
mined by the relative affinity for the Ru nucleus of the po-
tential substituting ligand in the solution (DMSO in our
study). It has been suggested that in vivo, the cellular en-
vironment may present other potential ligands such as
glutathione, which may facilitate release of the CO (Clark
et al, 2003). Therefore, the route of CO-RM administration
and tissue localization is likely to play an important role in
determining the availability of CO from these donor
compounds.
The time course and concentration dependence for the
release of CO from the CO-RM have been previously char-
acterized by Motterlini et al (2002). They detected approx-
imately 0.7 mol of CO liberated from 1 mol [Ru(CO)3Cl2]2 by
capturing the CO in a myoglobin solution. Using nuclear
magnetic resonance spectroscopy, they also identified a
dicarbonyl monomer, Ru(CO)2(DMSO)Cl2, when the CO-RM
was solubilized in DMSO, demonstrating the capacity of
DMSO theoretically to liberate 1 mol of CO from the CO-RM
molecule. The time course of CO release reached a plateau
at 60 min, a pattern of CO release that mirrors the loss of the
yellow color of [Ru(CO)3Cl2]2 solution that we observed, and
supports the concept that the colorimetric change indicated
the CO-RM degradation and CO release. Our evidence that
the degraded colorless product applied at 500 mM was
slightly but significantly immunosuppressive was unexpect-
ed, and the mechanism for such immunosuppression needs
to be established. This subtle immunosuppressive effect
was absent at the lower concentrations. It may be relevant
that cytotoxicity in vitro of the CO-RM/DMSO has been re-
ported with cultured vascular smooth muscle cells at high
concentrations of 4400 mM, although only after prolonged
24 h exposure (Motterlini et al, 2002), during which time
it can be assumed that a degradation product like
Ru(CO)2(DMSO)Cl2 was accumulating in the culture media.
The in vitro cytotoxicity was not observed when the cells
were treated with the metal ion alone in the form of RuCl3,
nor with DMSO.
It appears, however, that the 500 mM aged CO-RM may
have retained some CO ligands that could be further liber-
ated because, rather than exacerbating the SSUVR
immunosuppression, the aged CO-RM solution displayed
a slight, although not statistically significant protection
against SSUVR-induced immunosuppression. Because the
aged CO-RM did not appear to protect against cis-UCA-
induced immunosuppression, we surmise that CO-RM ap-
plied topically to the skin remained in the skin until its ex-
posure to SSUVR 1 h later, and that the irradiation facilitated
the liberation of further CO from the molecule. Such
photodissociation and CO release from other metal car-
bonyls have been reported (Hughey et al, 1975; Wrighton
and Ginley, 1975), and might be advantageous if topical
CO-RM were to be used therapeutically to protect from
photoimmunosuppression. Further studies should clarify
the potential for [Ru(CO)3Cl2]2 to undergo photolysis on the
skin, and the waveband of light that might activate this
reaction.
The mechanism of action of CO and its precise molecular
target(s) remain controversial. Currently two possible path-
ways have been described, via either the p38 protein of
MAPK, or the soluble guanylyl cyclase, which is a hemo-
protein and a defined receptor for another gaseous signal-
ling molecule, nitric oxide. The p38 MAPK inhibitor
SB203580 was shown to abrogate CO-mediated cytopro-
tection in rat hepatic ischemia/reperfusion injury, and there
is recent evidence that CO protection was mediated by the
selective activation of the MKK3/p38b protein MAPK path-
way (Otterbein et al, 2000; Amersi et al, 2002; Otterbein
et al, 2003b). We did not find that SB203580 altered the UVA
protection against SSUVR-suppressed CHS, and thus no
evidence for the p38 pathway being activated immunolog-
ically by UVA radiation. SB203580 inhibits only selective
isoforms of p38, however, and the unaffected p38 may have
remained active (Otterbein et al, 2003). On the other hand,
other investigators have demonstrated that CO, like nitric
oxide, binds to and activates guanylyl cyclase to produce
cGMP (Kharitonov et al, 1995; Steiner et al, 2001). This is
supported by reports that CO-mediated protection against
lethal ischemic lung injury in mice was abrogated in the
presence of the guanylyl cyclase inhibitor ODQ. Our studies
in mouse skin suggest that the immunoprotective properties
of CO act via this guanylyl cyclase pathway, because UVA
immunoprotection against SSUVR was antagonized by
ODQ, and CO-RM application increased the cutaneous
cGMP concentration. Interestingly, a recent study reports
that UVB-induced cell death and apoptosis in cultured
mouse and human keratinocytes was reduced by an ex-
ogenous nitric oxide donor, inhibitable by ODQ, consistent
with a protective role for the guanylyl cyclase pathway in the
skin (Weller et al, 2003). Future studies may reveal tissue or
stressor specificities for CO target pathways. Future studies
in the skin might also lead to methods by which the CO-
protective pathway might be harnessed to inhibit the de-
velopment of photoimmunosuppression from chronic solar
UVB exposure, and thus reduce the cutaneous cancer risk
in humans.
In summary, these studies have identified that the pho-
toimmunoprotective product of UVA-induced cutaneous HO
activity is the gaseous molecule CO. Our results demon-
strate that the murine cutaneous immune system is mod-
ulated by CO in vivo, possibly via the activation of soluble
guanylyl cyclase, and evidence for the activity of this mech-
anism, stimulated by UVA irradiation, should now be sought
in human skin.
Materials and Methods
Mice Female inbred albino Skh:hr-I hairless mice, age 8–12 wk
old, were provided from the Veterinary Science breeding colony.
They were maintained under conventional animal house conditions
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in wire-topped plastic cages on compressed paper bedding
(Fibrecycle Pty, Mudgeeraba, Queensland, Australia) at an ambi-
ent temperature of 251C, and under gold lighting (GEC F40GO) that
does not emit any UVB radiation, on a 12 h on/off cycle. They were
fed stock laboratory mouse pellets (Norco Stockfeeds, Lismore,
New South Wales, Australia) and tap water ad libitum. All proce-
dures were approved by the University of Sydney Animal Ethics
Committee and complied with the State Animal Research Act
1985.
UV radiation The UVA source and its spectral properties have
been described (Reeve and Domanski, 2002), and consisted of a
planar bank of seven 120 cm fluorescent UVA tubes (Hitachi 40W
F40T10BL, Tokyo, Japan) held in a reflective batten at 19 cm above
the irradiation table. The radiation was filtered through a selected
sheet of 6 mm window glass to block contaminating wavelengths
below 320 nm. Irradiance was measured with a IL 5000 radiometer
(International Light Inc. Newburyport, Massachusetts), with UVA
and UVB detectors (SE 015/UVA and SEE 240/UVB) calibrated to
the spectral irradiances of the sources. This source provided
2.7  103 W per cm2 UVA and 2.3  108 W per cm2 UVB. The
SSUVR source consisted of one UVB tube (Phillips TL-40W/12 RS,
Eindhoven, the Netherlands) flanked by two banks of three UVA
tubes, and the radiation was filtered through a sheet of 0.125 mM
cellulose acetate filter (Eastman Chemical Products, Kingsport,
Tennessee) to block contaminating wavelengths below 290 mm.
This source provided 3.43  103 W per cm2 UVA and 2.14  104
W per cm2 UVB. The sources were allowed to stabilize for 15 min
after switching on, and the temperature in the irradiation area be-
low the lamps was controlled by an electric fan. Groups of up to
five mice were placed in a box containing food and water, and
exposed to 387 kJ per m2 of UVA radiation (4 h exposure; equiv-
alent to the UVA content of approximately 6–8  minimal ery-
themal dose (MED) of sunlight in humans (Reeve and Tyrrell, 1999)),
or exposed to SSUVR containing 63.8 kJ per m2 UVA radiation and
3.98 kJ per m2 UVB radiation (31 min exposure, or approximately
3  MED). The UVA-alone dose was suberythemogenic, and could
reasonably be absorbed by a human during a day of sunbathing
through a UVB-absorbing sunscreen; the SSUVR dose resulted in
a moderate but non-burning edematous erythema at 24 h.
Cis-UCA treatment Trans-urocanic acid (Sigma-Aldrich, Castle
Hill, New South Wales, Australia) was photoisomerized in DMSO
solution to an equilibrium mixture of 60% trans- and 40% cis-
isomers as previously described (Reeve et al, 1993). A simple
cosmetic oil-in-water lotion (Reeve et al, 1993) containing 0.2%
(wt/vol) UV-irradiated urocanic acid, called ‘‘cis-urocanic’’ acid
here, 0.01 M phosphate-buffered saline at pH 7.2, and 5% DMSO
was prepared and stored in the dark at 41C. The control base lotion
was identical in composition, without added urocanic acid. Al-
iquots of 0.2 mL (400 mg urocanic acid) of either lotion were spread
evenly over the mouse dorsum using a 1 mL syringe (no needle)
and allowed to be absorbed for 30 min. Three applications were
made within 24 h, to produce an immunosuppressive response
similar to a single SSUVR exposure.
Treatment with CO The ‘‘CO-RM’’ tricarbonyldichlororuthenium
(II) dimer ([Ru(CO)3Cl2]2) (Sigma-Aldrich), here referred to as CO-
RM, was dissolved in DMSO and incorporated into base lotion to
provide a lotion containing 500 mM CO-RM and 10% (vol/vol)
DMSO. The fresh CO-RM/DMSO solution is yellow; however, it
becomes colorless as it ages and the CO is released from the
molecule and becomes available to the target tissue (Motterlini
et al, 2002). The degradation of the CO-RM/DMSO, probably to
Ru(CO)2(DMSO)Cl2 monomer as determined by nuclear magnetic
resonance analysis by Motterlini et al (2002), was observed spec-
trophotometrically (SpectraMax 250 plate reader, Molecular De-
vices Corp., Sunnybank, California) at room temperature at 405 nm
in a glass well for 3 h. To account for any effect that the degraded
CO-RM might have, a control lotion was prepared using the col-
orless product of the CO-RM/DMSO that had been aged for 4 wk
in the dark at room temperature, instead of the fresh CO-RM/
DMSO.
Groups of mice were treated topically on days 1–5 with 0.2 mL
freshly prepared CO-RM lotion at concentrations between 50 and
500 mM, or with lotion containing the CO-RM vehicle (DMSO) only,
or with 500 mM aged CO-RM lotion, spread over the dorsum. One
hour later, on day 1, groups of mice were irradiated with SSUVR, or
received topical applications of cis-UCA lotion (or its control lotion)
on the dorsum. To eliminate the contribution of endogenously
released CO from the constitutive HO activity, or from the UVA
component of SSUVR, some groups of mice were injected sub-
cutaneously on the ventrum with 15 mg per kg body weight (0.38
mg per mouse) of a specific inhibitor of this enzyme, SnPP (Po-
rphyrin Products, Logan, Utah), immediately following SSUVR or
cis-UCA treatment, and again 19 h later, as previously described
(Reeve and Tyrrell, 1999). Control mice were injected with the
NaOH/saline vehicle only.
Induction of CHS All mice were sensitized with 0.1 mL of 2%
oxazolone in ethanol applied to the non-irradiated and non-treated
ventral skin on days 8 and 9 following the SSUVR or cis-UCA
treatment (Reeve and Tyrrell, 1999). On day 15, ear thickness was
measured (pre-challenge) using a spring micrometer (Interapid,
Geneva, Switzerland), followed by application of 5 mL of 2% ox-
azolone in ethanol to each surface of both pinnae. The peak ear
swelling for the control treatments was determined by measuring
ear thickness repeatedly during 18–24 h post-challenge (post-
challenge ear thicknesspre-challenge ear thickness), and the
group average ear swelling of all treated mice was determined at
this time point.
Dose responsiveness of CO-RM effect Fresh CO-RM lotions of
50, 125, 250, and 500 mM were applied daily for 5 consecutive
days. Immunosuppression was induced on day 1 by three appli-
cations within 24 h of cis-UCA lotion, as above, and CHS to ox-
azolone was induced and elicited as described above. cis-UCA
was chosen as the immunosuppressive agent rather than SSUVR,
which contains UVA radiation that could produce endogenous CO
from induced HO-1 activity. Control mice received the same con-
centration of CO-RM without cis-UCA treatment.
Treatment with specific inhibitors The guanylyl cyclase inhibitor,
ODQ (Sigma-Aldrich), and the p38 MAPK inhibitor SB203580
(Calbiochem, Croydon, Victoria, Australia) were each dissolved
in DMSO, and then incorporated into the base lotion for topical
application. The final lotions contained 10% DMSO and 10 mM
ODQ or 10 mM SB203580, and the control lotion contained
only DMSO. Aliquots of 200 mL were applied to the dorsal skin
immediately following UV irradiation or cis-UCA treatment
and prior to the applications of the CO-RM, daily for the next
4 d. The CHS response was induced on days 8 and 9 following the
SSUVR.
To support that CO released from topical CO-RM was available
to activate a relevant biological target in the skin, groups of three
mice were treated with topical 500 mM CO-RM lotion daily for 3 d,
or received 10 mM ODQ application (inhibitor of soluble guanylyl
cyclase) 30 min prior to the CO-RM. Skin was taken 3 h after the
last CO-RM application, frozen, homogenized, freed of protein and
fat, and the supernatant was analyzed for cGMP by a commercial
ELISA kit (R&D Systems, Minneapolis, Missouri).
Statistics The significance of the differences between treatment
groups was evaluated using ANOVA followed by analysis by the
Tukey (HSD) test (XLSTAT program) with a confidence range of
95%.
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